266 related articles for article (PubMed ID: 15292529)
1. Protein oxidation status in patients with ankylosing spondylitis.
Yazici C; Köse K; Calis M; Kuzugüden S; Kirnap M
Rheumatology (Oxford); 2004 Oct; 43(10):1235-9. PubMed ID: 15292529
[TBL] [Abstract][Full Text] [Related]
2. Increased advanced oxidation protein products in Behçet's disease: a new activity marker?
Yazici C; Köse K; Caliş M; DemIr M; Kirnap M; Ateş F
Br J Dermatol; 2004 Jul; 151(1):105-11. PubMed ID: 15270878
[TBL] [Abstract][Full Text] [Related]
3. Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis.
Baskol G; Demir H; Baskol M; Kilic E; Ates F; Karakukcu C; Ustdal M
Cell Biochem Funct; 2006; 24(4):307-11. PubMed ID: 16142689
[TBL] [Abstract][Full Text] [Related]
4. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.
Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
J Rheumatol; 1999 Apr; 26(4):980-4. PubMed ID: 10229432
[TBL] [Abstract][Full Text] [Related]
5. A novel approach in psoriasis: first usage of known protein oxidation markers to prove oxidative stress.
Yazici C; Köse K; Utaş S; Tanrikulu E; Taşlidere N
Arch Dermatol Res; 2016 Apr; 308(3):207-12. PubMed ID: 26842230
[TBL] [Abstract][Full Text] [Related]
6. Respective role of uraemic toxins and myeloperoxidase in the uraemic state.
Capeillère-Blandin C; Gausson V; Nguyen AT; Descamps-Latscha B; Drüeke T; Witko-Sarsat V
Nephrol Dial Transplant; 2006 Jun; 21(6):1555-63. PubMed ID: 16476719
[TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
8. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
9. Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors.
Valli A; Suliman ME; Meert N; Vanholder R; Lindholm B; Stenvinkel P; Watanabe M; Barany P; Alvestrand A; Anderstam B
Clin Chim Acta; 2007 Apr; 379(1-2):87-94. PubMed ID: 17292872
[TBL] [Abstract][Full Text] [Related]
10. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP).
Chiu-Braga YY; Hayashi SY; Schafranski M; Messias-Reason IJ
Int J Cardiol; 2006 May; 109(2):275-6. PubMed ID: 15946754
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
Song IH; Rudwaleit M; Listing J; Sieper J
Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus.
Morgan PE; Sturgess AD; Davies MJ
Arthritis Rheum; 2005 Jul; 52(7):2069-79. PubMed ID: 15986354
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
[TBL] [Abstract][Full Text] [Related]
14. Advanced oxidation protein products: a novel marker of oxidative stress in ulcerative colitis.
Baskol M; Baskol G; Koçer D; Ozbakir O; Yucesoy M
J Clin Gastroenterol; 2008 Jul; 42(6):687-91. PubMed ID: 18574392
[TBL] [Abstract][Full Text] [Related]
15. The effect of infliximab on oxidative stress in chronic inflammatory joint disease.
Túnez I; Feijóo M; Huerta G; Montilla P; Muñoz E; Ruíz A; Collantes E
Curr Med Res Opin; 2007 Jun; 23(6):1259-67. PubMed ID: 17559725
[TBL] [Abstract][Full Text] [Related]
16. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
[TBL] [Abstract][Full Text] [Related]
17. Value of the peripheral blood B-cells subsets in patients with ankylosing spondylitis.
Lin Q; Gu JR; Li TW; Zhang FC; Lin ZM; Liao ZT; Wei QJ; Cao SY; Li L
Chin Med J (Engl); 2009 Aug; 122(15):1784-9. PubMed ID: 19781326
[TBL] [Abstract][Full Text] [Related]
18. Protein thiol oxidation and lipid peroxidation in patients with uraemia.
Prakash M; Upadhya S; Prabhu R
Scand J Clin Lab Invest; 2004; 64(6):599-604. PubMed ID: 15370466
[TBL] [Abstract][Full Text] [Related]
19. Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome.
Skvarilová M; Bulava A; Stejskal D; Adamovská S; Bartek J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Jun; 149(1):83-7. PubMed ID: 16170393
[TBL] [Abstract][Full Text] [Related]
20. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.
Mathieu S; Joly H; Baron G; Tournadre A; Dubost JJ; Ristori JM; Lusson JR; Soubrier M
Rheumatology (Oxford); 2008 Aug; 47(8):1203-7. PubMed ID: 18524805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
